Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.

Kumar K, Wigfield S, Gee HE, Devlin CM, Singleton D, Li JL, Buffa F, Huffman M, Sinn AL, Silver J, Turley H, Leek R, Harris AL, Ivan M.

J Mol Med (Berl). 2013 Jun;91(6):749-58. doi: 10.1007/s00109-013-0996-2. Epub 2013 Jan 30.

2.

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS.

J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.

3.

Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.

Zhou F, Hu J, Shao JH, Zou SB, Shen SL, Luo ZQ.

J Cancer Res Clin Oncol. 2012 Nov;138(11):1879-90. doi: 10.1007/s00432-012-1270-7. Epub 2012 Jun 27.

PMID:
22736027
4.

Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.

Gardner ER, Kelly M, Springman E, Lee KJ, Li H, Moore W, Figg WD.

Invest New Drugs. 2012 Feb;30(1):90-7. doi: 10.1007/s10637-010-9520-5. Epub 2010 Sep 7.

PMID:
20820910
5.

Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.

Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR, Weissleder R, Rabkin SD, Martuza RL.

Mol Ther. 2012 Jan;20(1):37-45. doi: 10.1038/mt.2011.187. Epub 2011 Sep 13.

6.

HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts.

Hartwich J, Orr WS, Ng CY, Spence Y, Morton C, Davidoff AM.

J Pediatr Surg. 2013 Jan;48(1):39-46. doi: 10.1016/j.jpedsurg.2012.10.016.

7.

Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.

Cao S, Durrani FA, Toth K, Rustum YM, Seshadri M.

Oral Oncol. 2011 Jun;47(6):459-66. doi: 10.1016/j.oraloncology.2011.04.001. Epub 2011 May 6.

8.

MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.

Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Soukharev S, Gingles N, Peterson N, Fazenbaker C, Woods R, Jallal B, Ricketts SA, Lavallee T, Coats S, Chang Y.

Int J Oncol. 2012 May;40(5):1321-30. doi: 10.3892/ijo.2012.1366. Epub 2012 Feb 10.

PMID:
22327175
9.

Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.

Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK.

Clin Cancer Res. 2013 Apr 1;19(7):1773-83. doi: 10.1158/1078-0432.CCR-12-1281. Epub 2013 Jan 10.

10.

A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma.

Gyanchandani R, Ortega Alves MV, Myers JN, Kim S.

Mol Cancer Res. 2013 Dec;11(12):1585-96. doi: 10.1158/1541-7786.MCR-13-0358. Epub 2013 Oct 3.

11.

Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.

Miyazaki S, Kikuchi H, Iino I, Uehara T, Setoguchi T, Fujita T, Hiramatsu Y, Ohta M, Kamiya K, Kitagawa K, Kitagawa M, Baba S, Konno H.

Int J Cancer. 2014 Jul 15;135(2):295-307. doi: 10.1002/ijc.28686. Epub 2014 Jan 6.

12.

Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.

Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF.

Clin Cancer Res. 2013 Aug 15;19(16):4392-403. doi: 10.1158/1078-0432.CCR-12-1557. Epub 2013 Jun 26.

13.

Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.

Kuroda J, Kuratsu J, Yasunaga M, Koga Y, Kenmotsu H, Sugino T, Matsumura Y.

Clin Cancer Res. 2010 Jan 15;16(2):521-9. doi: 10.1158/1078-0432.CCR-09-2393. Epub 2010 Jan 12.

14.

Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma.

Guo XL, Li D, Sun K, Wang J, Liu Y, Song JR, Zhao QD, Zhang SS, Deng WJ, Zhao X, Wu MC, Wei LX.

J Mol Med (Berl). 2013 Apr;91(4):473-83. doi: 10.1007/s00109-012-0966-0. Epub 2012 Oct 10.

15.

Combined treatment strategies for microtubule stabilizing agent-resistant tumors.

Broggini-Tenzer A, Sharma A, Nytko KJ, Bender S, Vuong V, Orlowski K, Hug D, O'Reilly T, Pruschy M.

J Natl Cancer Inst. 2015 Feb 17;107(4). pii: dju504. doi: 10.1093/jnci/dju504. Print 2015 Apr.

PMID:
25694444
16.

Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations.

Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, Engebraaten O.

Clin Cancer Res. 2014 Jan 15;20(2):404-12. doi: 10.1158/1078-0432.CCR-13-1865. Epub 2013 Nov 5.

17.

Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma.

Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, Aghi MK.

Cancer Res. 2012 Apr 1;72(7):1773-83. doi: 10.1158/0008-5472.CAN-11-3831. Epub 2012 Mar 23.

18.

Dichloroacetate induces tumor-specific radiosensitivity in vitro but attenuates radiation-induced tumor growth delay in vivo.

Zwicker F, Kirsner A, Peschke P, Roeder F, Debus J, Huber PE, Weber KJ.

Strahlenther Onkol. 2013 Aug;189(8):684-92. doi: 10.1007/s00066-013-0354-x. Epub 2013 Jun 23.

PMID:
23793865
19.

Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.

Wang W, Sivakumar W, Torres S, Jhaveri N, Vaikari VP, Gong A, Howard A, Golden EB, Louie SG, Schönthal AH, Hofman FM, Chen TC.

Neurosurg Focus. 2015 Mar;38(3):E8. doi: 10.3171/2015.1.FOCUS14743.

PMID:
25727230
20.

Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.

Sudaka A, Susini A, Lo Nigro C, Fischel JL, Toussan N, Formento P, Tonissi F, Lattanzio L, Russi E, Etienne-Grimaldi MC, Merlano M, Milano G.

Invest New Drugs. 2013 Feb;31(1):59-65. doi: 10.1007/s10637-012-9834-6. Epub 2012 Jun 20.

PMID:
22714791

Supplemental Content

Support Center